2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow Relapsing-Remitting Multiple Sclerosis (RRMS): new trials by email Literature Review of Relapsing-Remitting Multiple Sclerosis (RRMS) trials Research Report on Relapsing-Remitting Multiple Sclerosis (RRMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab Daclizumab - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 3 | Terminated | Biogen | 41 | 2017-04-18 | 2019-09-27 |
| MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone fingolimod, glatiramer acetate - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Terminated | Novartis Pharmaceuticals | 1064 | 2012-08-09 | 2019-05-28 |
Multiple Sclerosis, Relapsing-Remitting (2) · Multiple Sclerosis (1)
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Immune System Diseases (2) · Nervous System Diseases (2) · Multiple Sclerosis (1)
Coat Protein Complex I (1) · Daclizumab (1) · Fingolimod Hydrochloride (1) · Glatiramer Acetate (1)
Biogen (1) · Novartis Pharmaceuticals (1)
Canada (2) · Puerto Rico (2) · United States (2) · Argentina (1) · Brazil (1) · Chile (1) · Germany (1) · Italy (1) · Mexico (1)
2016 (1)